Zum Hauptinhalt wechseln

Leider unterstützen wir Ihren Browser nicht vollständig. Wenn Sie die Möglichkeit dazu haben, nehmen Sie bitte ein Upgrade auf eine neuere Version vor oder verwenden Sie Mozilla Firefox, Microsoft Edge, Google Chrome oder Safari 14 bzw. eine neuere Version. Wenn Sie nicht dazu in der Lage sind und Unterstützung benötigen, senden Sie uns bitte Ihr Feedback.

Wir würden uns über Ihr Feedback zu diesen neuen Seiten freuen.Sagen Sie uns, was Sie denken

Elsevier
Bei Elsevier publizieren

Optimize R&D outcomes in pharma & biotech with Elsevier data and tools

Elsevier helps R&D teams make confident drug development decisions. Gain critical insights from innovative AI workspaces and tools built on trusted evidence and domain expertise. R&D teams at 90%+ of the top pharma companies use Elsevier solutions.

Connect with our experts
Researchers looking toward a computer monitor

  • Die Zusammenarbeit mit Elsevier war eine Freude. Sie haben uns Daten bereitgestellt, die wir in unseren proprietären biomedizinischen Wissensgraphen integrieren, sowie wertvolle Expertise in Data Science und Drug Repurposing.

    David Fajgenbaum

    Mitgründer/Präsident bei EveryCure

  • F&E-Teams benötigen schnellen Zugang zu verifizierbarer wissenschaftlicher Evidenz … LeapSpace fördert Gründlichkeit und Transparenz, indem es in seinen Antworten nachvollziehbare Quellenangaben bereitstellt.

    Victoria Ball

    Associate Director, Global Library Services bei Incyte

  • Mit Reaxys können wir Strukturen suchen und herunterladen, sie mit Bioaktivitätsdaten verknüpfen und Struktur-Wirkungs-Beziehungen untersuchen. Reaxys gibt uns die Sicherheit, keine wichtigen Erkenntnisse zu übersehen.

    Dr. Christine Richardson

    Principal Scientist bei Sygnature Discovery

  • Dans Embase by Elsevier, vos mots-clés sont automatiquement associés aux termes Emtree pertinents. C’est un outil essentiel pour des recherches bibliographiques efficaces, avec des résultats complets et précis.

    Dr. med. Katharina Friedrich

    Beraterin für Regulatory Affairs und Medical Writing

AI-powered R&D solutions for pharma and biotech

Jan Erik Timmermann

Jetzt ansehen

Elsevier helps pharma and biotech teams bring innovations to market faster with end-to-end risk management. Our R&D solutions include biomedical and chemistry databases, curated datasets, predictive and analytical tools, and a research-grade AI workspace — LeapSpace. LeapSpace unifies key research workflows in one secure environment:

  • Explore complex scientific questions

  • Compare evidence and perspectives

  • Upload and analyze your own documents

  • Identify collaborators and topic experts

Designed to prioritize trust, privacy and security, LeapSpace enables faster discovery with confidence.

Talk to us about LeapSpace

Target identification and validation — Is our target druggable?

Science, people and tablet in lab for investigation

Elsevier curates, enriches and connects deep biological and translational data, so you can evaluate target-disease relevance with greater confidence early in discovery. Elsevier data for target identification and validation includes:

  • 18.6M biological relationships

  • Normalized data from ClinicalTrials.gov and public databases

  • Therapeutic area evidence from full-text literature (e.g., oncology, diabetes)

Explore biological, clinical, safety and competitive intelligence data — including early human trials — to identify risks sooner. Elsevier helps teams prioritize high-value targets and improve downstream success rates.

Talk to us about R&D solutions for target discovery

Hit identification to lead optimization — Are we advancing the most promising leads?

Cellular therapy

Elsevier connects chemistry data with biomedical evidence so you can progress confidently from hit identification through lead optimization. Elsevier data for hit identification to lead optimization includes:

  • Detailed experimental procedures for reactions, substances and bioactivities

  • 5.5M extracted safety and PK data lines

Surface ADME, off-target and liability signals to de-risk compounds before committing to a series. Explore structure-activity relationships and integrate biological insights to refine leads with greater precision. Elsevier helps teams prioritize the most promising series and avoid costly late-stage failures.

Talk to us about R&D solutions for hit to lead

Preclinical development — Have we surfaced translational risks?

Elsevier helps preclinical teams agree on research strategies with a higher probability of clinical translation by integrating high-quality chemistry, biology and safety evidence. Elsevier data for preclinical development includes:

  • Chemistry and biology data enriched with DMPK, ADME and toxicology research

Explore the chemical space linked to PK and liability trends. Connect targets and pathways to safety concerns, understand toxicity mechanisms and predict potential drug-drug interactions. Elsevier helps teams address safety and developability earlier — before costly experiments begin.

Talk to us about R&D solutions for preclinical teams

Clinical development — Do we have the evidence needed to de-risk clinical trials?

Female doctor giving instructions about prescription medicine to patient

Elsevier helps clinical development teams design stronger clinical trials with robust safety, feasibility and regulatory evidence. Elsevier data for clinical development includes:

  • Prior trial endpoints, dosing patterns, comparator choices, safety outcomes and translational research

Anticipate exposure- and dose-related risks to reduce costly early-phase rework. Monitor emerging risks across compound classes and competitors to translate preclinical insights into clinical strategies with greater clarity. Elsevier helps teams strengthen trial design and make confident, defensible decisions.

Talk to us about R&D solutions for clinical development

Regulatory approval and post-market surveillance — Are we ahead of safety risks?

View of Earth from space

Elsevier helps pharmacovigilance, regulatory and safety teams detect safety signals earlier and make defensible decisions with regulator-ready evidence. Elsevier data for regulatory approval and post-market surveillance includes:

  • Richly indexed global biomedical literature and regulatory documents for precise, reproducible evidence

Conduct comprehensive literature reviews using full-text journal articles, conference abstracts and grey literature. Monitor adverse events, emerging safety signals and real-world performance with traceable, audit-ready citations. Elsevier helps you detect, assess and validate safety signals with greater speed and rigor.

Talk to us about R&D solutions for safety and regulatory teams

Elsevier helps pharma and biotech impact-makers succeed